Literature DB >> 7206588

[The pharmacokinetics of adriamycin and adriamycin-metabolites (author's transl)].

G Ehninger, H J Stocker, B Proksch, K Wilms.   

Abstract

A sensitive reproducible, nondestructive method for the determination of adriamycin and its metabolites in plasma, leukocytes and tissues has been developed. Apolar substances as adriamycinone (adm-one) were extracted at pH 2 with chloroform, polar ones as adriamycin (adm) and adriamycinol (adm-ol) at pH 8.8 with chloroform: methanol, separated by thin-layer-chromatography and quantitated by fluorescence spectrophotometry. The plasma levels of adm-ol and adm-one were lower in all patients compared to those of adm. Further metabolites were found in the bile. Toxic effects were found in patients with prolonged half-lives in the elimination phase. A delayed elimination was observed in a patient with an elevation of the bilirubin level, but also in patients without overt liver disease. The pharmacokinetics of adm showed considerable inter- and intraindividual fluctuations.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7206588     DOI: 10.1007/bf01477050

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  28 in total

1.  Adriamycin and 5-fluorouracil in the treatment of advanced hepatoma: a Southwest Oncology Group study.

Authors:  L H Baker; J H Saiki; S E Jones; J S Hewlett; R W Brownlee; R L Stephens; V K Vaitkevicius
Journal:  Cancer Treat Rep       Date:  1977-11

2.  Clinical effects and pharmacokinetics of different dosage schedules of adriamycin.

Authors:  W A Creasey; L S McIntosh; T Brescia; O Odujinrin; G T Aspnes; E Murray; J C Marsh
Journal:  Cancer Res       Date:  1976-01       Impact factor: 12.701

3.  Analysis of the pharmacokinetic characteristics, pharmacological and chemotherapeutic activity of 14-Hydroxy-daunomycin (Adriamycin), a new drug endowed with an antitumour activity.

Authors:  E Arena; N D'Alessandro; L Dusonchet; N Gebbia; F Gerbasi; M Palazzoadriano; A Raineri; L Rausa; E Tubaro
Journal:  Arzneimittelforschung       Date:  1971-08

4.  Pharmacokinetics and metabolism of adriamycin in man.

Authors:  R S Benjamin; C E Riggs; N R Bachur
Journal:  Clin Pharmacol Ther       Date:  1973 Jul-Aug       Impact factor: 6.875

5.  Distribution and excretion of adriamycin in man.

Authors:  G Di Fronzo; L Lenaz; G Bonadonna
Journal:  Biomedicine       Date:  1973-04-10

6.  Daunomycin and adriamycin metabolism via reductive glycosidic cleavage.

Authors:  M A Asbell; E Schwartzbach; F J Bullock; D W Yesair
Journal:  J Pharmacol Exp Ther       Date:  1972-07       Impact factor: 4.030

7.  Identification of new metabolites of daunomycin and adriamycin.

Authors:  F J Bullock; R J Bruni; M A Asbell
Journal:  J Pharmacol Exp Ther       Date:  1972-07       Impact factor: 4.030

8.  Separation of leukocytes from blood and bone marrow. Introduction.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

9.  Experience with the use of adriamycin in combination with other anticancer agents using a weekly schedule, with particular reference to lack of cardiac toxicity.

Authors:  A J Weiss; R W Manthel
Journal:  Cancer       Date:  1977-11       Impact factor: 6.860

10.  Daunorubicin metabolism: estimation of daunorubicin reductase.

Authors:  N R Bachur; D H Huffman
Journal:  Br J Pharmacol       Date:  1971-12       Impact factor: 8.739

View more
  15 in total

1.  Pharmacokinetics of adriamycin, adriamycinol, and antipyrine in patients with moderate tumor involvement of the liver.

Authors:  R Preiss; M Matthias; R Sohr; B Brockmann; H Hüller
Journal:  J Cancer Res Clin Oncol       Date:  1987       Impact factor: 4.553

2.  Doxorubicin and doxorubicinol: intra- and inter-individual variations of pharmacokinetic parameters.

Authors:  J M Jacquet; F Bressolle; M Galtier; M Bourrier; D Donadio; J Jourdan; J F Rossi
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

3.  In vitro effects of perifosine, bortezomib and lenalidomide against hematopoietic progenitor cells from healthy donors.

Authors:  Martin Schmidt-Hieber; Robert Dabrowski; Babette Aicher; Philipp Lohneis; Antonia Busse; Carola Tietze-Buerger; Birgit Reufi; Eckhard Thiel; Igor Wolfgang Blau
Journal:  Invest New Drugs       Date:  2011-07-13       Impact factor: 3.850

4.  Pharmacokinetic study of i.v. infusions of adriamycin.

Authors:  S Eksborg; H S Strandler; F Edsmyr; I Näslund; P Tahvanainen
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

5.  Evaluation of cytostatic drug concentrations in the kidney, bladder wall, and prostate by means of the diffusion chamber technique in dogs.

Authors:  P Porpaczy; C P Schmidbauer; A Georgopoulos; H Rameis; T A Endler
Journal:  Urol Res       Date:  1983

6.  Acute cardiac toxicity in patients after doxorubicin treatment and the effect of combined tocopherol and nifedipine pretreatment.

Authors:  R Lenzhofer; U Ganzinger; H Rameis; K Moser
Journal:  J Cancer Res Clin Oncol       Date:  1983       Impact factor: 4.553

7.  Early-phase pharmacokinetics of doxorubicin in non-Hodgkin lymphoma patients. Dose-dependent and time-dependent pharmacokinetic parameters.

Authors:  J Robert; B Hoerni; P Vrignaud; C Lagarde
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

8.  Intrahepatic and intravenous administration of adriamycin--a comparative pharmacokinetic study in patients with malignant liver tumours.

Authors:  S Eksborg; B J Cedermark; H S Strandler
Journal:  Med Oncol Tumor Pharmacother       Date:  1985

Review 9.  Anthracycline antitumour agents. A review of physicochemical, analytical and stability properties.

Authors:  J Bouma; J H Beijnen; A Bult; W J Underberg
Journal:  Pharm Weekbl Sci       Date:  1986-04-25

10.  Protein binding of anthraquinone glycosides, with special reference to adriamycin.

Authors:  S Eksborg; H Ehrsson; B Ekqvist
Journal:  Cancer Chemother Pharmacol       Date:  1982-12       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.